Business Description
Hunan Fangsheng Pharmaceutical Co Ltd
ISIN : CNE100001VG6
Compare
Compare
Traded in other countries / regions
603998.China IPO Date
2014-12-05Description
Hunan Fangsheng Pharmaceutical Co Ltd is engaged in pharmaceutical business. The company's business scope covers the production and sales of tablets, capsules, granules, oral suspension, powder, suppository, powder-injection, tinctures, spray lotion, small volume injections, and bulk pharmaceutical chemicals. Its product offerings include Cefixime Tablets, Cefpiramide for Injection, Cefprozil Tablets, Fleroxacin Dispersible Tablets, and others.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.4 | |||||
| Equity-to-Asset | 0.47 | |||||
| Debt-to-Equity | 0.48 | |||||
| Debt-to-EBITDA | 3.15 | |||||
| Interest Coverage | 9.32 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.7 | |||||
| Beneish M-Score | -2.8 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.8 | |||||
| 3-Year EBITDA Growth Rate | 22.3 | |||||
| 3-Year EPS without NRI Growth Rate | 41.3 | |||||
| 3-Year Book Growth Rate | 7.3 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 72.39 | |||||
| 9-Day RSI | 60.02 | |||||
| 14-Day RSI | 53.38 | |||||
| 6-1 Month Momentum % | 0.81 | |||||
| 12-1 Month Momentum % | -1.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.85 | |||||
| Quick Ratio | 0.55 | |||||
| Cash Ratio | 0.24 | |||||
| Days Inventory | 261.66 | |||||
| Days Sales Outstanding | 53.73 | |||||
| Days Payable | 185.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.83 | |||||
| Dividend Payout Ratio | 0.81 | |||||
| 3-Year Dividend Growth Rate | 42.9 | |||||
| Forward Dividend Yield % | 2.83 | |||||
| 5-Year Yield-on-Cost % | 79.18 | |||||
| 3-Year Average Share Buyback Ratio | -0.8 | |||||
| Shareholder Yield % | -0.38 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 69.56 | |||||
| Operating Margin % | 13.79 | |||||
| Net Margin % | 11.85 | |||||
| FCF Margin % | -0.42 | |||||
| ROE % | 13.29 | |||||
| ROA % | 6.25 | |||||
| ROIC % | 8.23 | |||||
| ROC (Joel Greenblatt) % | 22.92 | |||||
| ROCE % | 11.94 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 25.58 | |||||
| PE Ratio without NRI | 25.4 | |||||
| Shiller PE Ratio | 36.07 | |||||
| Price-to-Owner-Earnings | 125 | |||||
| PEG Ratio | 1.2 | |||||
| PS Ratio | 3.02 | |||||
| PB Ratio | 3.16 | |||||
| Price-to-Tangible-Book | 4.87 | |||||
| Price-to-Operating-Cash-Flow | 25.58 | |||||
| EV-to-EBIT | 21.1 | |||||
| EV-to-EBITDA | 21.1 | |||||
| EV-to-Revenue | 3.03 | |||||
| EV-to-FCF | -730.23 | |||||
| Price-to-Projected-FCF | 3.11 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.02 | |||||
| Price-to-Graham-Number | 2.35 | |||||
| Earnings Yield (Greenblatt) % | 4.74 | |||||
| FCF Yield % | -0.15 | |||||
| Forward Rate of Return (Yacktman) % | 20.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hunan Fangsheng Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,630.137 | ||
| EPS (TTM) (Â¥) | 0.43 | ||
| Beta | 1.16 | ||
| Volatility % | 45.85 | ||
| 14-Day RSI | 53.38 | ||
| 14-Day ATR (Â¥) | 0.404844 | ||
| 20-Day SMA (Â¥) | 10.6325 | ||
| 12-1 Month Momentum % | -1.57 | ||
| 52-Week Range (Â¥) | 7.12 - 13.09 | ||
| Shares Outstanding (Mil) | 439.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hunan Fangsheng Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hunan Fangsheng Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hunan Fangsheng Pharmaceutical Co Ltd Frequently Asked Questions
What is Hunan Fangsheng Pharmaceutical Co Ltd(SHSE:603998)'s stock price today?
The current price of SHSE:603998 is ¥11.00. The 52 week high of SHSE:603998 is ¥13.09 and 52 week low is ¥7.12.
When is next earnings date of Hunan Fangsheng Pharmaceutical Co Ltd(SHSE:603998)?
The next earnings date of Hunan Fangsheng Pharmaceutical Co Ltd(SHSE:603998) is .
Does Hunan Fangsheng Pharmaceutical Co Ltd(SHSE:603998) pay dividends? If so, how much?
The Dividend Yield %  of Hunan Fangsheng Pharmaceutical Co Ltd(SHSE:603998) is 2.83% (As of Today), Highest Dividend Payout Ratio of Hunan Fangsheng Pharmaceutical Co Ltd(SHSE:603998) was 1.13. The lowest was 0.07. And the median was 0.4. The  Forward Dividend Yield % of Hunan Fangsheng Pharmaceutical Co Ltd(SHSE:603998) is 2.83%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers